A new landmark clinical trial from Standford Medicine shows that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.The trial involved 4,401 participants in 34 countries.
“For the first time in 18 years, we have a therapy for patients with Type 2 diabetes and chronic kidney disease that decreases kidney failure,” says Dr. Kenneth Mahaffey, professor of medicine at the Stanford University School of Medicine and co-principal investigator of the trial.
“Now, patients with diabetes have a promising option to guard against one of the most severe risks of their condition,” he added.
The drug, canagliflozin, improves on a nearly two-decades-old therapy that is currently the only treatment approved to protect kidney function in people with Type 2 diabetes. In the trial, canagliflozin also was found to reduce the risk of major cardiovascular events.
Canagliflozin increases the excretion of glucose through the kidneys. It has already been approved by the Food and Drug Administration to lower blood glucose in patients with Type 2 diabetes and to reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes and existing heart disease.
A paper describing the findings of the clinical trial was published today The New England Journal of Medicine.
The trial will be presented at the International Society of Nephrology’s World Congress of Nephrology in Melbourne, Australia.
Mahaffey, who is director of the Stanford Center for Clinical Research, is the study’s senior author. The lead author is Dr. Vlado Perkovic, executive director of The George Institute for Global Health Australia, and a professor of medicine at the University of New South Wales in Sydney.
Definitive Trial Results
“People with diabetes and kidney disease are at extremely high risk of kidney failure, heart attack, stroke, and death,” Perkovic said. “With this definitive trial result, we now have a very effective way to reduce this risk using a once-daily pill.”
Participants in the trial received the best care available for kidney disease under current guidelines, a type of therapy called renin-angiotensin-aldosterone system, or RAAS, blockade.
In addition, half were randomly selected to receive canagliflozin, while the other half were given a placebo.
The primary results of the study found that participants who took canagliflozin were 30 percent less likely than the placebo group to develop kidney failure or die from either renal failure or cardiovascular disease.
Their risk of kidney failure or death from kidney failure was reduced by 34 percent, and the risk of hospitalization for heart failure or death due to cardiac causes decreased by 31 percent.
People with diabetes can develop kidney disease because prolonged high blood sugar harms blood vessels in the kidney. In addition, diabetes often causes high blood pressure, which can stretch and weaken blood vessels in the organ.
For the past two decades, physicians have largely relied on RAAS blockade to prevent the deterioration of kidney function in diabetic patients.
Although RAAS blockade lowers blood pressure and delays progression of kidney disease, patients undergoing this treatment remain at high risk for renal failure and cardiovascular disease, as well as death from these conditions.
Given that the number of people with Type 2 diabetes worldwide is estimated to rise by 20 percent to 510 million in 2030, “a drug like canagliflozin that improves both cardiovascular and renal outcomes has been eagerly sought by both patients with Type 2 diabetes and clinicians caring for them,” Mahaffey added.